#United States #New York #Securities Fraud #Pomerantz LLP #ADMA Biologics

Pomerantz Law Firm Investigates ADMA Biologics, Inc. Investors' Claims

In a recent development, Pomerantz LLP has initiated an investigation focused on claims regarding potential securities fraud linked to ADMA Biologics, Inc. (NASDAQ: ADMA), a prominent player in the biopharmaceutical industry. This investigation is a response to allegations suggesting that ADMA may have engaged in deceptive business practices that could materially affect its shareholders. Investors who believe they have been impacted are encouraged to reach out to the firm for further assistance.

Background of the Investigation

The investigation stems from a report published by Culper Research on March 24, 2026, which alleged that ADMA's claimed growth figures are misleading and primarily attributed to a suspected channel stuffing scheme. This report raises significant concerns, indicating that, contrary to the reported revenue growth of 20% in 2025, the actual revenues could have experienced a decline of 3% without the alleged manipulations.

Following this report, ADMA's stock saw a dramatic plunge, decreasing by $2.26 per share, a staggering 16.63%, resulting in a closing price of $11.33. This initial shock was compounded by Cantor Fitzgerald's decision to downgrade ADMA's stock on March 26, citing the company's unsatisfactory response to the allegations. This downgrade further triggered a $1.34 decline in share value, leading to a closing price of $8.29.

On May 6, 2026, in light of evolving market dynamics in the U.S. plasma products and immunoglobulin sector, ADMA withdrew its long-term financial guidance. This announcement led to another drop in share value by $1.61, marking a 15.97% fall to a closing price of $8.47 on May 7, 2026. These successive downturns underscore the potential volatility and risk facing ADMA's investors amidst the ongoing scrutiny and allegations.

The Role of Pomerantz LLP

With a reputable history in corporate, securities, and antitrust litigation, Pomerantz LLP has established itself as a leading firm dedicated to safeguarding shareholders' rights. Founded over 85 years ago by Abraham L. Pomerantz, who is known as a pioneer in securities class action lawsuits, the firm has fought rigorously for victims of corporate misconduct and securities fraud.

Pomerantz's team is well-versed in navigating complex financial landscapes and has succeeded in securing multimillion-dollar recoveries for its clients. The firm's ongoing commitment is to ensure that investors receive the justice they deserve, particularly in light of deceitful corporate practices that can compromise their financial interests.

How to Get Involved

Investors of ADMA Biologics, Inc. who feel they have been wronged or have pertinent information regarding these allegations are advised to contact Daniel Peyton directly at Pomerantz LLP via [email protected] or by calling 646-581-9980, ext. 7980. Engaging with Pomerantz may provide them the opportunity to join the class action and potentially reclaim losses incurred due to the outlined deceptive practices.

Conclusion

The investigation into ADMA Biologics by Pomerantz LLP illuminates critical concerns about transparency and integrity in the biopharmaceutical sector. As corporate governance becomes more scrutinized, investors must stay informed and vigilant about the practices of companies in which they invest. The unfolding situation with ADMA serves as a pertinent reminder of the potential risks involved in the investment landscape and highlights the necessity for legal advocacy in defending investor rights.